Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

Authors:
Address: Mapp Biopharmaceutical, San Diego, CA 92121, USA. larry.zeitlin@mappbio.com
Journal:


Publication:
Free Text: Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.

abstract

No countermeasures currently exist for the prevention or treatment of the severe sequelae of Filovirus (such as Ebola virus; EBOV) infection. To overcome this limitation in our biodefense preparedness, we have designed monoclonal antibodies (mAbs) which could be used in humans as immunoprotectants for EBOV, starting with a murine mAb (13F6) that recognizes the heavily glycosylated mucin-like domain of the virion-attached glycoprotein (GP). Point mutations were introduced into the variable region of the murine mAb to remove predicted human T-cell epitopes, and the variable regions joined to human constant regions to generate a mAb (h-13F6) appropriate for development for human use. We have evaluated the efficacy of three variants of h-13F6 carrying different glycosylation patterns in a lethal mouse EBOV challenge model. The pattern of glycosylation of the various mAbs was found to correlate to level of protection, with aglycosylated h-13F6 providing the least potent efficacy (ED(50) = 33 μg). A version with typical heterogenous mammalian glycoforms (ED(50) = 11 μg) had similar potency to the original murine mAb. However, h-13F6 carrying complex N-glycosylation lacking core fucose exhibited superior potency (ED(50) = 3 μg). Binding studies using Fcγ receptors revealed Enhanced binding of nonfucosylated h-13F6 to mouse and human FcγRIII. Together the results indicate the presence of Fc N-glycans enhances the protective efficacy of h-13F6, and that mAbs manufactured with uniform glycosylation and a higher potency glycoform offer promise as biodefense therapeutics.



Related Articles
Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
J Virol. 2007
Influences of glycosylation on antigenicity, immunogenicity, and protective efficacy of ebola virus GP DNA vaccines.
Dowling W, Thompson E, Badger C, Mellquist JL, Garrison AR, Smith JM, Paragas J, Hogan RJ, Schmaljohn C. J Virol. 2007 Feb; 81(4):1821-37. Epub 2006 Dec 6.
Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody.
PLoS One. 2011
Rapid high yield production of different glycoforms of Ebola virus monoclonal antibody.
Castilho A, Bohorova N, Grass J, Bohorov O, Zeitlin L, Whaley K, Altmann F, Steinkellner H. PLoS One. 2011; 6(10):e26040. Epub 2011 Oct 24.
Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain.
J Mol Biol. 2008
Complex of a protective antibody with its Ebola virus GP peptide epitope: unusual features of a V lambda x light chain.
Lee JE, Kuehne A, Abelson DM, Fusco ML, Hart MK, Saphire EO. J Mol Biol. 2008 Jan 4; 375(1):202-16. Epub 2007 Oct 16.
A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.
Proc Natl Acad Sci U S A. 2011
A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.
Phoolcharoen W, Dye JM, Kilbourne J, Piensook K, Pratt WD, Arntzen CJ, Chen Q, Mason HS, Herbst-Kralovetz MM. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):20695-700. Epub 2011 Dec 5.
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
J Virol. 2006
Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.
Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, et al. J Virol. 2006 Mar; 80(6):2738-46.
A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.
Proc Natl Acad Sci U S A. 2011
A nonreplicating subunit vaccine protects mice against lethal Ebola virus challenge.
Phoolcharoen W, Dye JM, Kilbourne J, Piensook K, Pratt WD, Arntzen CJ, Chen Q, Mason HS, Herbst-Kralovetz MM. Proc Natl Acad Sci U S A. 2011 Dec 20; 108(51):20695-700. Epub 2011 Dec 5.

To top Home


Show map | Diseases | Vaccination | Chronic disease | Medicine | Pregnancy | Heat & Sunburn | Cold | Security | Useful tips | Faq | News

TraveldoctorOnline 2001 • Disclaimer webmaster

The contents within traveldoctoronline are presented only for informational purposes and cannot substitute for professional health care or any other medical treatment.All users of this website with health problems should be oblige always to consult their medical doctor before starting any treatment.